VolitionRx is a clinical diagnostics company developing easy-to-use and cost-effective blood tests to diagnose a range of diseases in humans and animals including sepsis and cancer. Diagnostic Nu.Q tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid.
Healthcare |
edison tv
Healthcare |
Update
Healthcare |
edison tv
Healthcare |
edison tv
Cameron Reynolds
CEO
Jake Micallef
Chief Scientific Officer
Scott Powell
Director of IR
Terig Hughes
CFO
Forecast net debt (US$m)
1.6
Forecast gearing ratio (%)
94
% | 1M | 3M | 12M |
---|---|---|---|
Actual | 4.8 | 13.3 | (2.1) |
Relative | (1.0) | 9.1 | (26.7) |
52 week high/low | US$1.2/US$0.5 |
VolitionRx continues to make headway in growing a body of clinical evidence to build Nu.Q® NETs as a potential breakthrough tool in sepsis. These efforts, coupled with its CE mark in Europe, are a strong foundation in rapid and simplified sepsis detection that seeks to address the limitations and complexities of the current standard of care. Sepsis (immune-system triggered organ dysfunction) has a worrisome prevalence, affecting c 50 million per year with a mortality rate of c 20–25%, exceeding the combination of many leading cancers. Further, every hour of delayed treatment increases the chances of mortality of this preventable condition by c 8%. In this note we recap VolitionRx’s recent clinical updates, as we look forward to near-term improvements in early sepsis detection.
Y/E Dec | Revenue (US$m) | EBITDA (US$m) | PBT (US$m) | EPS (c) | P/E (x) | P/CF (x) |
---|---|---|---|---|---|---|
2018A | 0.0 | (17.9) | (18.0) | (57.37) | N/A | N/A |
2019A | 0.0 | (16.1) | (16.1) | (41.09) | N/A | N/A |
2020E | 0.0 | (17.2) | (17.4) | (42.61) | N/A | N/A |
2021E | 0.1 | (18.6) | (18.8) | (44.46) | N/A | N/A |